Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald F Watts

Showing results (61-70 of 706) with videos related to

Pageof 71
Sort By:
European Journal of Preventive Cardiology|March 6, 2024
Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?Gerald F Watts, Dick C Chan
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 23, 2003
Measurement and application of arterial stiffness in clinical research: focus on new methodologies and diabetes mellitusRichard J Woodman, Gerald F Watts
Clinical Science (London, England : 1979)|July 11, 2003
Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significanceGerald F Watts, Thomas H Marwick
Atherosclerosis|October 2, 2018
Improving the global care of familial hypercholesterolaemia: Starting the ball rollingKausik K Ray, Gerald F Watts
Metabolism: Clinical and Experimental|September 28, 2011
Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the boxDick C Chan, Gerald F Watts
Current Vascular Pharmacology|January 29, 2008
Pharmacological regulation of dyslipoproteinaemia in insulin resistant statesDick C Chan, Gerald F Watts
Current Opinion in Lipidology|January 17, 2008
Nutrition and metabolism: non-alcoholic fatty liver disease - pathogenesis, cardiovascular risk and therapyGerald F Watts, Seng Khee Gan
Diabetes, Obesity & Metabolism|July 25, 2017
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular diseaseMichael M Page, Gerald F Watts
Expert Opinion on Therapeutic Targets|January 18, 2007
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?John R Burnett, Gerald F Watts
Expert Opinion on Pharmacotherapy|July 16, 2010
Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapiesDick C Chan, Gerald F Watts
Pageof 71

Showing results (61-70 of 706) with videos related to

Sort By:
Pageof 71
European Journal of Preventive Cardiology|March 6, 2024
Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?Gerald F Watts, Dick C Chan
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 23, 2003
Measurement and application of arterial stiffness in clinical research: focus on new methodologies and diabetes mellitusRichard J Woodman, Gerald F Watts
Clinical Science (London, England : 1979)|July 11, 2003
Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significanceGerald F Watts, Thomas H Marwick
Atherosclerosis|October 2, 2018
Improving the global care of familial hypercholesterolaemia: Starting the ball rollingKausik K Ray, Gerald F Watts
Metabolism: Clinical and Experimental|September 28, 2011
Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the boxDick C Chan, Gerald F Watts
Current Vascular Pharmacology|January 29, 2008
Pharmacological regulation of dyslipoproteinaemia in insulin resistant statesDick C Chan, Gerald F Watts
Current Opinion in Lipidology|January 17, 2008
Nutrition and metabolism: non-alcoholic fatty liver disease - pathogenesis, cardiovascular risk and therapyGerald F Watts, Seng Khee Gan
Diabetes, Obesity & Metabolism|July 25, 2017
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular diseaseMichael M Page, Gerald F Watts
Expert Opinion on Therapeutic Targets|January 18, 2007
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?John R Burnett, Gerald F Watts
Expert Opinion on Pharmacotherapy|July 16, 2010
Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapiesDick C Chan, Gerald F Watts
Pageof 71